One of Tachi's newly born legacy biotechs raises $135M and enlists an A-list board to advance late-stage vaccine
Tachi is gone, but his legacy biotechs are continuing to make news.
This morning it’s the newly born HilleVax — a creation of Takeda and Frazier Healthcare Partners, where Tachi Yamada was respectively CSO and a longtime partner — that’s taking a big step forward to late-stage testing of its norovirus vaccine with a $135 million crossover megaraise. HilleVax CEO Rob Hershberg — who became Celgene CSO and BD chief after they bought out his earlier startup, VentiRx — is at the helm. And the startup crew has attracted some star talent to the board of what will remain a relatively small, closely focused biotech team looking to take the long, traditional route to a vaccine approval.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.